Tumor Imaging Metrics Core Facility (DF/HCC)
Director: Harris, Gordon J., Ph.D.; Van Den Abbeele, Annick D., M.D.
Location: 25 New Chardon Street Suite 501, Boston, MA 02114
The Tumor Imaging Metrics Core (TIMC), co-Directed by Annick D. Van den Abbeele, MD (DFCI) and Gordon J. Harris, PhD (MGH), is a shared resource that was founded in 2004 to provide standardized, longitudinal tumor metrics for patients enrolled in oncologic clinical trials across the five Harvard teaching hospitals of the DF/HCC. The ordering, communication, workflow, results reporting, electronic signatures, audit trails, criteria conformance, and chargeback billing are all managed through a web-based informatics platform, Precision Imaging Metrics, developed by TIMC, which is currently in use at six NCI-designated Cancer Centers around the country. Clinical trials imaging assessment results are provided in time for review at the point of care in as little as one hour after completion of scanning. TIMC currently manages over 1,000 active clinical trials and performs over 12,000 image assessments per year for Partners and DF/HCC investigators. The mission of the Tumor Imaging Metrics Core (TIMC) is to provide standardized, consistent, longitudinal radiological measurements to evaluate therapeutic response for DF/HCC clinical trials.
The TIMC -
* Makes reliable, quantitative, longitudinal measurements (such as RECIST, Lugano, irRC, RANO,
standardized uptake value SUV etc.) of lesions from serial MRI, CT, PET, and PET/CT scan images
* Presents results of analyses on a password-protected secure web-based report
* Provides an independent service, with verifiable measurement of treatment response for patients enrolled in cancer center trials
* Serves as a centralized, computerized resource to facilitate efficient internal or external auditing
Director: Harris, Gordon J., Ph.D.
Phone: (617) 726-9464
Director: Van Den Abbeele, Annick D., M.D.
Phone: (617) 632-2595
|Facilities and Equipment:|
Location of Core: 25 New Chardon Street Suite 501, Boston, MA 02114
- HERMES workstation
- Merge Healthcare eFilm workstation
- Precision Imaging Metrics Manager
- Vitrea workstation
- Consultation services for image-based protocol and image analysis design
- Image scan aggregation and management service
- Imaging Assessment Criteria for Oncology Clinical Trials
mRECIST for HCC
mRECIST for Mesothelioma
mRECIST (based on irRC)
PCWG2 + RECIST 1.0
PCWG2 + RECIST 1.1
Revised Cheson (2007)
Lymphoma PET SUVmax
IMWG (for multiple myeloma)
IPCG (radiological assessment only)
- Quality Control
For site review, the TIMC paradigm utilizes one central reader per radiologic exam (single read). The central reader will be randomly assigned and cannot be selected by trial staff based on site location.
A mediation process has been established in the instance that the central review is felt to be discordant with clinical assessment. Trial staff should file a request for mediation with the TIMC Help Desk (email@example.com) which will trigger a review by a blinded, independent reviewer at a site where the patient is not enrolled.
A randomly selected subset of imaging studies are reviewed by dedicated TIMC staff to ensure that documentation was made to justify discordance between central radiology and clinical reviews. Additionally, data are reviewed to ensure appropriate disease was selected at baseline and that follow-up assessments were rendered according to established criteria.
- Radiology reviewer training
Radiologists and Image Analysts are trained and certified as proficient in established response assessment criteria and clinical research principles.
- Reporting and database management service of radiological data for clinical trials
Clinical trial staff can access the secure, password-protected website -any scan, anytime, anywhere- to request scan assessments and view results, including annotated images and graphs.
- Standardized lesion measurement
Standardized, longitudinal image measurement of radiological scans for oncology clinical trials.
|Departmental Web Link(s):|